Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma

Padcev for urothelial cancer treatment
Enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck) have been given accelerated approval by the Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

Share This Post

May 2023: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck) have been given accelerated approval by the Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

Efficacy was assessed in the multi-cohort (dose escalation cohort, Cohort A, Cohort K) research EV-103/KEYNOTE-869 (NCT03288545). Patients were treated with enfortumab vedotin-ejfv + pembrolizumab in the dose escalation cohort and Cohort A, whereas in Cohort K, patients were randomised to either the combination or enfortumab vedotin-ejfv alone. Patients were ineligible for chemotherapy that contained cisplatin because they had not previously undergone systemic treatment for locally progressed or metastatic illness. 121 individuals in total received pembrolizumab together with enfortumab vedotin-ejfv.

Objective response rate (ORR) and duration of response (DoR), which were determined by blinded independent central review using RECIST v1.1, were the key efficacy outcome measures. In 121 patients, the confirmed ORR was 68% (95% CI: 59, 76), with 12% of patients achieving full responses. The dosage escalation cohort and Cohort A had a median DoR of 22 months (interquartile range: 1+ to 46+), while Cohort K did not reach the median DoR (interquartile range: 1 to 24+).

Increased glucose, increased aspartate aminotransferase, rash, decreased haemoglobin, increased creatinine, peripheral neuropathy, decreased lymphocytes, fatigue, increased alanine aminotransferase, decreased sodium, increased lipase, decreased albumin, alopecia, decreased phosphate, decreased weight, diarrhoea, pruritus, decreased appetite, nausea, dysgeusia, decreased potassium, decreased sodium were the most frequent adverse reactions (>20%), along with

When combined with pembrolizumab, the recommended dose of enfortumab vedotin-ejfv is 1.25 mg/kg (up to 125 mg for patients under 100 kg), given intravenously over 30 minutes on Days 1 and 8 of a 21-day cycle until disease progression or intolerable toxicity. After receiving enfortumab vedotin on the same day, the dosage of pembrolizumab is advised to be 200 mg every three weeks or 400 mg every six weeks until the disease progresses, there is intolerable toxicity, or up to 24 months have passed.

View full prescribing information for Padcev and Keytruda

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/